Your biceps and your left ventricle are not separate projects. A December 2025 state-of-the-art review in JACC Advances maps the shared biology of skeletal muscle aging (sarcopenia) and cardiac muscle aging. Same mitochondria. Same low-grade inflammation. Same anabolic resistance. Same hormonal drift.
That pairing matters clinically. Sarcopenia is not a vanity diagnosis. It tracks with heart failure with preserved ejection fraction, exercise intolerance, and higher mortality. If we only treat lipids and ignore muscle, we miss half the organ system.
What actually goes wrong
After about age 50, skeletal muscle mass drops roughly 1% to 2% per year, and faster after 60. Muscle becomes less responsive to protein and to training. That is anabolic resistance: about 25% to 30% less protein synthesis for the same stimulus. Mitochondria make less ATP and more reactive oxygen species. Satellite cells, the repair crew, get fewer and slower. Chronic inflammaging (TNF-alpha, IL-6, IL-1) turns on protein breakdown and turns down building.
The heart runs a parallel program: fewer cardiomyocytes, fibrosis, stiffer ventricles, sloppy calcium handling, the same mitochondrial decay. Heart failure with preserved ejection fraction in older adults is, in part, this biology.
Hormones sit in the middle. Falling sex steroids and growth-hormone signaling push both tissues toward a catabolic, fibrotic state. That is one reason I measure them instead of guessing.
What moves the needle
No drug is FDA-approved for sarcopenia. The review is clear: the backbone is multimodal, not a pill.
Progressive resistance training, 2 to 3 times a week, plus aerobic work and balance. Resistance is the cornerstone. Walking alone is not enough to protect type II fibers.
Protein that matches age, not the old RDA. For most older adults, 1.0 to 1.2 g/kg/day. With acute or chronic disease, 1.2 to 1.5 g/kg/day. Leucine-rich sources help (about 2.5 to 3 g leucine per meal). Plant vs animal protein is less important than total dose and resistance work. Kidney disease changes this. Do not copy a bodybuilder protocol onto a low eGFR.
Fix the deficiencies. Vitamin D repletion helps strength when you are actually deficient, not when you are already replete. Testosterone, when hypogonadism is documented, can increase lean mass and walk distance. It is not a sarcopenia drug for everyone.
Treat the heart as part of the muscle program. Optimize the cardiac condition, review polypharmacy (drugs that cause orthostasis and deconditioning), and do not wait weeks after a hospitalization to start moving.
What I do not want this to become
This is not a pitch for SARMs, myostatin inhibitors, or unmonitored hormone stacks. Those remain investigational or indication-specific. Wearables are interesting and still sloppy in the real world.
The practical ask: if you are over 50, your muscle is cardiovascular tissue. Grip strength, sit-to-stand, gait speed, protein intake, and a real lifting stimulus belong in the same conversation as blood pressure and lipids.
Kalra K, Berchie P, Singh S, et al. Skeletal muscle-cardiac muscle aging: shared mechanisms and multimodal interventions. JACC Adv. 2025;4(12):102347.
https://doi.org/10.1016/j.jacadv.2025.102347
This is educational, not medical advice for your specific case.
